Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis

He Huang; Min Chen; Wenjuan Wu; Tianhui Yang; Hao Liu; Zhengwei Zhu; Wenjun Wang; Sen Yang; Xian Ding; Hui Wang; Yujun Sheng; Yaohua Zhang; Min Li; Xuejun Zhang

doi:10.1097/CM9.0000000000002390

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis

Chin Med J (Engl). 2023 Feb 5;136(3):360-361. doi: 10.1097/CM9.0000000000002390.

Authors

He Huang^{1

2

3}, Min Chen⁴, Wenjuan Wu^{1

2

3}, Tianhui Yang^{1

2

3}, Hao Liu^{1

2

3}, Zhengwei Zhu^{1

3}, Wenjun Wang^{1

3}, Sen Yang^{1

2

3}, Xian Ding^{2

5}, Hui Wang^{2

5}, Yujun Sheng^{1

2

3}, Yaohua Zhang⁶, Min Li^{4

5}, Xuejun Zhang^{1

2

3

6}

Affiliations

¹ Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China.
² Ferry Institute of Dermatology, Hefei, Anhui 230000, China.
³ Boao Super Hospital Dermatology Center, Qionghai, Hainan 571437, China.
⁴ Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University, Suzhou Dushu Lake Hospital), Suzhou, Jiangsu 215125, China.
⁵ Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
⁶ Department of Dermatology, Institute of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
East Asian People*
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

ixekizumab
Antibodies, Monoclonal, Humanized